Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China.
Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China.
Int J Biol Sci. 2020 Mar 25;16(11):1767-1773. doi: 10.7150/ijbs.41105. eCollection 2020.
B7-H3 (also known as CD276) is a newly found molecule of B7 family, which may be a promising target for cancer treatment. B7-H3 protein was demonstrated to be expressed in several kinds of tumor tissues including non-small-cell lung cancer (NSCLC) and prostate cancer. Its expression is highly associated with undesirable treatment outcomes and survival time, due to function of the immune checkpoint molecule. It was classified as either a co-stimulatory molecule for T cell activation or the nonimmunological role of regulating signaling pathways. Although there is still no agreed conclusion on the function of B7-H3, it may be a valuable target for cancer therapy. This review aims to provide a comprehensive, up-to-date summary of the advances in B7-H3 targeting approaches in cancer therapy. Although several challenges remain, B7-H3 offers a new therapeutic target with increased efficacy and less toxicity in future cancer treatment.
B7-H3（也称为 CD276）是 B7 家族的一种新发现的分子，可能是癌症治疗的有前途的靶点。已经证明 B7-H3 蛋白在几种肿瘤组织中表达，包括非小细胞肺癌（NSCLC）和前列腺癌。由于免疫检查点分子的功能，其表达与不良的治疗结果和生存时间高度相关。它被归类为 T 细胞激活的共刺激分子或调节信号通路的非免疫作用。尽管关于 B7-H3 的功能仍然没有达成共识，但它可能是癌症治疗的有价值的靶点。本综述旨在提供癌症治疗中 B7-H3 靶向方法的最新进展的全面、最新的总结。尽管仍然存在一些挑战，但 B7-H3 在未来的癌症治疗中提供了一种具有更高疗效和更低毒性的新的治疗靶标。
